Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Dose Optimization in Imatinib-Resistant/Intolerant CP-CML
NCT00123474Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Primary completion
- Sep 2006
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up. Started Jul 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00123474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123474.